Menu
SOPHiA GENETICS™ is excited to be a part of the 31st International Precision Med Tri-Con Conference, held in person in San Diego, California from March 26th – 28th.
Stop by booth #124 for a chance to meet our experts, get a sneak peak into the capabilities of the SOPHiA DDM™ Platform and to discover the breadth of our liquid biopsy capabilities.
JLUNCHEON PRESENTATION
Unlocking access to MSK-ACCESS®: A decentralized approach to innovative liquid biopsy technology
Thursday, March 27 | 1:00 -1:30 pm | Liquid Biopsy Track
SOPHiA GENETICS is collaborating with MSK to decentralize MSK-ACCESS® for liquid biopsy. By combining MSK’s clinical expertise in cancer genomics and the predictive algorithms of the SOPHiA DDMTM Platform, we aim to expand access to precision cancer analysis capabilities worldwide. Join our expert speakers to gain insights into the clinical utility of liquid biopsy at MSK and explore the analytical performance data of MSK-ACCESS® powered with SOPHiA DDMTM – a decentralized application.
Speakers:
Rose Brannon, PhD – Director of Clinical Bioinformatics, Memorial Sloan Kettering Cancer Center (MSK)
Chloe Ryder, PhD – Product Manager for Liquid Biopsy, SOPHiA GENETICS
[et_pb_section fb_built="1" _builder_version="4.24.0" _module_preset="default" width="100%" custom_padding="||21px|||" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.24.0" _module_preset="default" width="91.4%" min_height="875.4px" custom_margin="|11px||60px||" custom_padding="||0px|||" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.24.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.24.0" _module_preset="default" min_height="364px" custom_padding="||0px|||" global_colors_info="{}" theme_builder_area="post_content"]
SOPHiA GENETICS is excited to be part of the 8th Annual Liquid Biopsy for Precision Oncology Summit, held in person in San Diego, CA, USA, from February 28 to March 1, 2024.
You will have the chance to chat with our experts and learn more about our collaboration with AstraZeneca and Memorial Sloan Kettering Cancer Center (MSK) to decentralize their MSK-ACCESS® assay.
TALK
Access to Precision Oncology with Decentralized Liquid Biopsy Solutions
Talk, February 29
12-12:30 PM
Track B: Clinical Development & Commercialization
[/et_pb_text][et_pb_text _builder_version="4.24.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
Liquid biopsy is emerging as a revolutionary technology, holding promise for swift and precise diagnostics. Despite the potential to positively impact precision oncology and the increasing popularity of NGS-based assays, liquid biopsy faces challenges, including workflow standardization across the globe, regulatory issues, guideline inclusion, and reimbursement hurdles.
Join us in this talk to hear about the SOPHiA GENETICS' journey in expanding access to Liquid Biopsy at a global scale.
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version="4.24.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.24.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_button button_url="https://www.addevent.com/event/qM20104787" button_text="SAVE THE DATE" button_alignment="center" _builder_version="4.24.0" _module_preset="default" custom_button="on" button_text_color="#FFFFFF" button_bg_color="#E3295C" button_border_color="#FFFFFF" button_font="||||||||" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_button][/et_pb_column][/et_pb_row][et_pb_row _builder_version="4.24.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.24.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.24.0" _module_preset="default" text_text_color="#E3295C" global_colors_info="{}" theme_builder_area="post_content"]
Learn more about our collaboration with AstraZeneca and MSK 
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built="1" custom_padding_last_edited="on|phone" _builder_version="4.24.0" _module_preset="default" background_color_gradient_direction="90deg" background_enable_image="off" display_conditions="W10=" custom_padding="0px||40px||false|false" custom_padding_tablet="" custom_padding_phone="20px||20px||true|false" custom_css_main_element=" display: flex;|| flex-direction: column;|| justify-content: center;" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row column_structure="1_3,2_3" make_equal="on" admin_label="about the author" _builder_version="4.23.4" background_color="#F3F5F6" background_size="initial" background_position="top_left" background_repeat="repeat" width="95%" max_width="800px" min_height="240px" custom_padding="|120px||120px|false|true" border_radii="on|15px|15px|15px|15px" saved_tabs="all" locked="off" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="1_3" _builder_version="4.22.2" custom_padding="|||" custom_css_main_element="display: flex;||align-items: center;" global_colors_info="{}" custom_padding__hover="|||" theme_builder_area="post_content"][et_pb_image src="https://www.sophiagenetics.com/wp-content/uploads/2024/02/T-Scott-1.png" title_text="T Scott" _builder_version="4.24.0" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.22.2" custom_padding="|||" custom_css_main_element="display: flex;||justify-content: center;||flex-direction: column;" global_colors_info="{}" custom_padding__hover="|||" theme_builder_area="post_content"][et_pb_text _builder_version="4.24.0" _module_preset="default" text_font="|700|||||||" text_font_size="26px" global_colors_info="{}" theme_builder_area="post_content"]
Presented by
[/et_pb_text][et_pb_text _builder_version="4.24.0" _module_preset="default" text_font="||||||||" text_text_color="#0A2E4A" text_font_size="16px" link_font="||||on||||" link_text_color="#FFFFFF" header_text_align="left" header_4_font="||||||||" header_4_text_align="left" header_4_text_color="#0A2E4A" header_4_font_size="19px" custom_margin="||1px|||" global_colors_info="{}" theme_builder_area="post_content"]
T. Scott Reid, PhD
[/et_pb_text][et_pb_text _builder_version="4.24.0" _module_preset="default" text_font="||||||||" text_text_color="#0A2E4A" text_font_size="16px" link_font="||||on||||" link_text_color="#FFFFFF" header_text_align="left" header_4_font="||||||||" header_4_text_align="left" header_4_text_color="#0A2E4A" header_4_font_size="19px" hover_enabled="0" global_colors_info="{}" theme_builder_area="post_content" sticky_enabled="0"]
VP & Global Head of Diagnostics
[/et_pb_text][et_pb_text _builder_version="4.24.0" _module_preset="default" text_font="||||||||" text_text_color="#0A2E4A" text_font_size="16px" link_font="||||on||||" link_text_color="#FFFFFF" header_text_align="left" header_4_font="||||||||" header_4_text_align="left" header_4_text_color="#0A2E4A" header_4_font_size="19px" global_colors_info="{}" theme_builder_area="post_content"]
SOPHiA GENETICS
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
SOPHiA GENETICS is excited to join the Society of Immunotherapy of Cancer annual meeting in person and online in San Diego, US. Join us at booth #635 November 3-5 to chat with our experts and experience the capabilities of the universal SOPHiA DDM™ Platform.
Mark your agenda on November 3rd at 12:15 p.m. for our satellite symposium:
“Multimodal data integration to advance personalized medicine in lung cancer: An overview of DLIV study”
[dgat_layout_shortcode id="281292"]
Over the last 20 years, targeted compounds have been proven effective for non-small cell lung cancer (NSCLC patients), but recent scientific breakthroughs have made immunotherapies a new pillar of cancer care. These recent advances, coupled with the avalanche of health data, have made it hard for medical professionals to identify the patient sub-groups that will benefit the most from immunotherapy, alone or in combination with chemotherapy, without experiencing significant side effects.
By using deep learning and artificial intelligence frameworks to integrate multiple biomarkers, SOPHiA GENETICS’ DEEP-Lung-IV study (NCT04994795) aims to improve the accuracy of prognosis and first-line treatment planning. Join us to discover how this study is helping medical researchers integrate different health data modalities in a meaningful way, breaking through data silos and expanding the power and reach of collective intelligence in healthcare.
As one of the Principal Investigators of the DEEP-Lung-IV Study (NCT04994795), Dr. Akerley will share his perspective on lung cancer care and his long-term vision for multimodal data integration in clinical routine.
DEEP-Lung-IV is a multicentric observational study leveraging the power of machine learning to integrate different data modalities and understand the prognosis and treatment responses of patients diagnosed with stage IV non-small cell lung cancer.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.